[go: up one dir, main page]

AR118842A2 - Composición farmacéutica que contiene tamoxifen y endoxifen y procedimiento para prepararla - Google Patents

Composición farmacéutica que contiene tamoxifen y endoxifen y procedimiento para prepararla

Info

Publication number
AR118842A2
AR118842A2 ARP200101246A ARP200101246A AR118842A2 AR 118842 A2 AR118842 A2 AR 118842A2 AR P200101246 A ARP200101246 A AR P200101246A AR P200101246 A ARP200101246 A AR P200101246A AR 118842 A2 AR118842 A2 AR 118842A2
Authority
AR
Argentina
Prior art keywords
endoxifen
pharmaceutical composition
composition containing
prepare
procedure
Prior art date
Application number
ARP200101246A
Other languages
English (en)
Inventor
Kristin Dickschen
Eiing Thomas Dr
Willmann Stefan Dr
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of AR118842A2 publication Critical patent/AR118842A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente se refiere a una composición farmacéutica de combinación en dosis fijas que contiene una sustancia original, cuya acción depende de la cantidad o de la actividad de las variantes de proteína expresadas, las variantes enzimáticas, las variantes del receptor o las variantes del transportador, y un metabolito de la misma, donde dicha sustancia original es tamoxifeno y dicho metabolito es endoxifeno. Reivindicación 3: Composición de acuerdo con la reivindicación 2 para pacientes del CYP2D6 IM, caracterizada porque comprende 15 - 25 mg de tamoxifeno y 0,25 - 2,00 mg de endoxifeno.
ARP200101246A 2012-06-01 2020-04-30 Composición farmacéutica que contiene tamoxifen y endoxifen y procedimiento para prepararla AR118842A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12170401.9A EP2668945A1 (de) 2012-06-01 2012-06-01 Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen

Publications (1)

Publication Number Publication Date
AR118842A2 true AR118842A2 (es) 2021-11-03

Family

ID=48520964

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP130101928 AR091234A1 (es) 2012-06-01 2013-05-31 Formulaciones farmaceuticas basadas en genotipos o fenotipos, procedimiento para prepararlas
ARP200101246A AR118842A2 (es) 2012-06-01 2020-04-30 Composición farmacéutica que contiene tamoxifen y endoxifen y procedimiento para prepararla

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP130101928 AR091234A1 (es) 2012-06-01 2013-05-31 Formulaciones farmaceuticas basadas en genotipos o fenotipos, procedimiento para prepararlas

Country Status (23)

Country Link
US (3) US10285958B2 (es)
EP (2) EP2668945A1 (es)
JP (2) JP6096289B2 (es)
KR (1) KR102129043B1 (es)
CN (2) CN110075097A (es)
AR (2) AR091234A1 (es)
AU (1) AU2013269793B2 (es)
BR (1) BR112014030059B1 (es)
CA (1) CA2875189C (es)
DK (1) DK2854789T3 (es)
ES (1) ES2744306T3 (es)
HK (1) HK1207296A1 (es)
HU (1) HUE045699T2 (es)
IL (1) IL235988B (es)
MX (1) MX370304B (es)
NZ (1) NZ702849A (es)
PL (1) PL2854789T3 (es)
PT (1) PT2854789T (es)
RU (1) RU2683260C2 (es)
SA (1) SA113340607B1 (es)
SG (2) SG11201407791VA (es)
TW (1) TWI644666B (es)
WO (1) WO2013178565A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2668945A1 (de) 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
US11965206B2 (en) 2018-12-21 2024-04-23 John Stoddard Method of dosing a patient with multiple drugs using adjusted phenotypes of CYP450 enzymes
WO2025194145A1 (en) * 2024-03-14 2025-09-18 Duke University Compositions comprising hepatocytes and methods of treating metabolic liver diseases and disorders

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1317546C (en) * 1985-07-01 1993-05-11 Werner Meier Pharmaceutical preparations containing mixtures of hydroxy derivatives of vitamin d
US6048857A (en) 1989-10-17 2000-04-11 Ellinwood, Jr.; Everett H. Dosing method of administering medicaments via inhalation administration
US5580728A (en) 1994-06-17 1996-12-03 Perlin; Mark W. Method and system for genotyping
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US6760708B1 (en) 1999-08-19 2004-07-06 Dell Products L.P. Method and system for migrating stored data to a build-to-order computing system
AU2001231091A1 (en) 2000-01-21 2001-07-31 Vincent P. Stanton Jr. Identification of genetic components of drug response
US7427480B2 (en) 2002-03-26 2008-09-23 Perlegen Sciences, Inc. Life sciences business systems and methods
US20070190022A1 (en) * 2003-08-29 2007-08-16 Bacopoulos Nicholas G Combination methods of treating cancer
US7504214B2 (en) * 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer
DE10345836A1 (de) 2003-10-02 2005-04-21 Bayer Technology Services Gmbh Verfahren zur Simulation der Wechselwirkung von chemischen Substanzen mit lebenden Organismen
JP4732683B2 (ja) 2003-12-29 2011-07-27 ユニバーサル・バイオ・リサーチ株式会社 標的物質の検出方法
US7169813B2 (en) 2004-03-18 2007-01-30 Fondazione IRCCS “Istituto Nazionale Dei Tumori” 4-oxo-fenretinide, administered alone and in combination with fenretinide, as preventive and therapeutic agent for cancer
US7805282B2 (en) 2004-03-30 2010-09-28 New York University Process, software arrangement and computer-accessible medium for obtaining information associated with a haplotype
DE102004025534A1 (de) 2004-05-25 2005-12-15 Bayer Technology Services Gmbh Verfahren zur (zweistufigen) Dosis- und Dosierungsfindung
US8024128B2 (en) 2004-09-07 2011-09-20 Gene Security Network, Inc. System and method for improving clinical decisions by aggregating, validating and analysing genetic and phenotypic data
US8147615B2 (en) 2004-11-05 2012-04-03 Infineon Technologies Ag Method of fabricating semiconductor cleaners
MX2007014963A (es) * 2005-06-02 2008-04-17 Biovail Lab Int Srl Composicion de liberacion modificada de al menos una forma de venlafaxina.
US20070122824A1 (en) 2005-09-09 2007-05-31 Tucker Mark R Method and Kit for Assessing a Patient's Genetic Information, Lifestyle and Environment Conditions, and Providing a Tailored Therapeutic Regime
EP1938231A1 (en) 2005-09-19 2008-07-02 BG Medicine, Inc. Correlation analysis of biological systems
RU2318508C2 (ru) * 2005-12-28 2008-03-10 Всеволод Иванович Киселев Фармацевтическая композиция для лечения и профилактики пролиферативных заболеваний молочной железы
FR2896896B1 (fr) 2006-02-02 2009-09-25 Commissariat Energie Atomique Procede de classification d'evenements ou d'etats en deux etapes
DE102006028232A1 (de) 2006-06-20 2007-12-27 Bayer Technology Services Gmbh Vorrichtung und Verfahren zur Berechnung und Bereitstellung einer Medikamentendosis
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
PL2101731T3 (pl) 2006-11-21 2018-07-31 Jina Pharmaceuticals Inc. Endoksyfen do zastosowania w leczeniu nowotworu
US8099298B2 (en) 2007-02-14 2012-01-17 Genelex, Inc Genetic data analysis and database tools
CA2716456A1 (en) 2008-02-26 2009-09-03 Purdue Research Foundation Method for patient genotyping
WO2009120999A2 (en) 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
US20100029734A1 (en) * 2008-05-06 2010-02-04 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment
AU2009267052B2 (en) 2008-06-30 2013-07-11 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
JP4517312B2 (ja) * 2008-07-08 2010-08-04 ソニー株式会社 メモリアクセス制御装置および撮像装置
US20110136913A1 (en) * 2008-08-19 2011-06-09 Goetz Matthew P Assessing and treating breast cancer patients
EP2346428B1 (en) 2008-09-25 2019-11-06 Zeltiq Aesthetics, Inc. Treatment planning systems and methods for body contouring applications
US7873482B2 (en) 2008-12-16 2011-01-18 Bruno Stefanon Diagnostic system for selecting nutrition and pharmacological products for animals
WO2010096834A2 (en) 2009-02-23 2010-08-26 Indiana University Research & Technology Corporation Materials and methods for treating patients with tamoxifen
WO2011072244A1 (en) * 2009-12-10 2011-06-16 Mount Sinai School Of Medicine Of New York University Method of treatment of breast cancer with tamoxifen
US9372198B2 (en) 2010-06-17 2016-06-21 Aradigm Corporation Diagnosis of entry of gastrointestinal contents into respiratory tract of humans and animals
RU2611662C2 (ru) * 2010-08-26 2017-02-28 Ипка Лэборэториз Лимитед Способы лечения или профилактики тромбообразования или эмболии
US20120329762A1 (en) * 2011-06-27 2012-12-27 Ashok Kumar Anti-thrombotic compounds
US10061887B2 (en) 2012-04-02 2018-08-28 Berg Llc Interrogatory cell-based assays and uses thereof
EP2668945A1 (de) 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
US9417221B2 (en) 2013-08-27 2016-08-16 International Business Machines Corporation Food steganography

Also Published As

Publication number Publication date
SG10201610072UA (en) 2017-01-27
SG11201407791VA (en) 2015-01-29
AU2013269793A1 (en) 2015-01-22
MX370304B (es) 2019-12-09
BR112014030059B1 (pt) 2022-12-06
US20150174082A1 (en) 2015-06-25
HUE045699T2 (hu) 2020-01-28
JP2015519350A (ja) 2015-07-09
EP2854789B1 (de) 2019-06-26
JP2017048234A (ja) 2017-03-09
JP6096289B2 (ja) 2017-03-15
RU2014154140A (ru) 2016-07-27
BR112014030059A2 (pt) 2017-07-25
EP2668945A1 (de) 2013-12-04
EP2854789A1 (de) 2015-04-08
US20170326081A1 (en) 2017-11-16
WO2013178565A1 (de) 2013-12-05
TWI644666B (zh) 2018-12-21
TW201400109A (zh) 2014-01-01
AU2013269793B2 (en) 2018-03-01
US10285958B2 (en) 2019-05-14
MX2014014596A (es) 2015-03-03
IL235988B (en) 2018-11-29
NZ702849A (en) 2016-09-30
CA2875189C (en) 2020-09-22
SA113340607B1 (ar) 2018-05-09
CN110075097A (zh) 2019-08-02
AR091234A1 (es) 2015-01-21
PT2854789T (pt) 2019-09-18
KR102129043B1 (ko) 2020-07-01
IL235988A0 (en) 2015-01-29
ES2744306T3 (es) 2020-02-24
CN104507464A (zh) 2015-04-08
PL2854789T3 (pl) 2019-12-31
DK2854789T3 (da) 2019-09-16
CA2875189A1 (en) 2013-12-05
HK1207296A1 (en) 2016-01-29
RU2683260C2 (ru) 2019-03-27
US20170326080A1 (en) 2017-11-16
KR20150022894A (ko) 2015-03-04

Similar Documents

Publication Publication Date Title
CR11740A (es) Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada
UY31747A (es) Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparacion
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
CL2010001526A1 (es) Compuestos derivados de isonicotinamida, moduladores de la estearoil-coa-desaturasa; composicion farmaceutica que comprende un compuesto;utiles para tratar enfermedades relacionadas con dislipidemia y trastornos del metabolismo de lipidos.
CU24032B1 (es) UNA FORMULACIÓN FARMACÉUTICA QUE COMPRENDE 4-[3-(4-CICLOPROPANOCARBONIL-PIPERAZINA-1-CARBONIL)-4-FLUOROBENCIL]-2h-FTALAZIN-1-ONA EN DISPERSIÓN SÓLIDA CON COPOVIDONA
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
BR112012032282A2 (pt) administração transdérmica de memantina
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
CL2012000026A1 (es) Formulación farmacéutica acuosa que contiene una insulina, un análogo de insulina o un derivado insulínico, o una de sus sales farmacológicamente tolerables, y metionina; proceso para preparar dicha formulación; medicamento que la contiene; y su uso para tratar la diabetes mellitus.
MX361778B (es) Composiciones farmaceuticas y metodos de tratamiento.
EP2832851A4 (en) IMMORTALIZED STEM CELLS AND MEDICAL COMPOSITION AND MEDICAMENT WITH A PRODUCT THEREOF AS AN ACTIVE SUBSTANCE
FI20116138A7 (fi) Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen
CO6351689A2 (es) Formulaciones farmaceuticas que contienen ligandos de receptores de dopamina
CY1122868T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν 2-αμινο-2-[2-(4-οκτυλοφαινυλ)αιθυλ]προπανο-1,3-διολη
BR112014011981A8 (pt) Formulações farmacêuticas sólidas orais, seus processos de preparação e usos
AR118842A2 (es) Composición farmacéutica que contiene tamoxifen y endoxifen y procedimiento para prepararla
BR112017008993A2 (pt) métodos e composições especificamente para o tratamento de transtorno de déficit de atenção
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
AR082312A1 (es) Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos
BR112014002025A2 (pt) partículas que compreendem compostos ativos com base em poliacrilato
CR20120549A (es) Composiciones farmacèuticas que comprenden hidromorfona y naloxona
NI201000189A (es) Formulación de medicamento sólido con liberación retardadas.
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal